<DOC>
	<DOCNO>NCT00058487</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy epirubicin use different way stop tumor cell divide stop grow die . Thalidomide may stop growth hepatocellular ( liver ) cancer stop blood flow tumor . Combining epirubicin thalidomide may kill tumor cell . PURPOSE : Phase II trial study effectiveness combine epirubicin thalidomide treat patient unresectable metastatic liver cancer .</brief_summary>
	<brief_title>Epirubicin Thalidomide Treating Patients With Liver Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine antitumor activity epirubicin thalidomide patient locally unresectable metastatic hepatocellular carcinoma . - Determine toxic effect regimen patient . OUTLINE : Patients receive epirubicin day 1 , 8 , 15 thalidomide day 1-21 . Courses repeat every 28 day . PROJECTED ACCRUAL : A total 12 patient per year accrue study .</detailed_description>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis hepatocellular carcinoma Locally unresectable metastatic disease Measurable disease No clinically apparent CNS metastases No carcinomatous meningitis PATIENT CHARACTERISTICS : Age Over 18 Performance status ECOG 02 Life expectancy At least 12 week Hematopoietic Absolute neutrophil count least 1,500/mm^3 Platelet count least 75,000/mm^3 Hepatic SGOT great 5 time upper limit normal Bilirubin great 3.0 mg/dL INR great 1.5* Albumin least 2.0 g/dL NOTE : *Not required patient receive full anticoagulation warfarin deep vein thrombosis pulmonary embolism Renal Creatinine great 2.0 mg/dL Cardiovascular No myocardial infarction within past 6 month LVEF normal echocardiogram MUGA Other Not pregnant nursing Fertile patient must use effective contraception Willing able participate System Thalidomide Education Prescribing Safety ( STEPS ) program No uncontrolled serious medical psychiatric illness No concurrent uncontrolled malignancy PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy No 1 prior chemotherapy regimen hepatocellular carcinoma No prior chemoembolization liver Endocrine therapy Not specify Radiotherapy Not specify Surgery More 2 week since prior major surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2006</verification_date>
	<keyword>adult primary hepatocellular carcinoma</keyword>
	<keyword>advanced adult primary liver cancer</keyword>
	<keyword>localize unresectable adult primary liver cancer</keyword>
	<keyword>recurrent adult primary liver cancer</keyword>
</DOC>